These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 37141329)

  • 21. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
    Yang Y; He L; Liu P; Wang J; Yang N; Li Z; Ping F; Xu L; Li W; Zhang H; Li Y
    Diabetes Obes Metab; 2024 Feb; 26(2):548-556. PubMed ID: 37860884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
    Xie Z; Zheng G; Liang Z; Li M; Deng W; Cao W
    Metabolism; 2024 Sep; 161():156038. PubMed ID: 39305981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
    Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
    Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
    Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
    Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.
    Yu D; Shen S; Zhang J; Wang Q
    Clin Ther; 2023 Aug; 45(8):787-796. PubMed ID: 37455226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues.
    Andraos J; Muhar H; Smith SR
    Rev Endocr Metab Disord; 2023 Dec; 24(6):1089-1101. PubMed ID: 37526853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspectives on weight control in diabetes - Tirzepatide.
    Várkonyi TT; Pósa A; Pávó N; Pavo I
    Diabetes Res Clin Pract; 2023 Aug; 202():110770. PubMed ID: 37279858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.
    Tall Bull S; Nuffer W; Trujillo JM
    J Diabetes Complications; 2022 Dec; 36(12):108332. PubMed ID: 36375235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.
    Permana H; Yanto TA; Hariyanto TI
    Diabetes Metab Syndr; 2022 Nov; 16(11):102640. PubMed ID: 36274410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incretin Analogs for Weight Management in Adults Without Diabetes.
    Lobkovich A; Kale-Pradhan P; Lipari M
    Ann Pharmacother; 2024 Apr; 58(4):398-406. PubMed ID: 37522468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
    Ma J; Liu M; Wang R; Du L; Ji L
    Diabetes Obes Metab; 2024 Apr; 26(4):1454-1463. PubMed ID: 38302718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.
    Lisco G; De Tullio A; Disoteo O; De Geronimo V; Piazzolla G; De Pergola G; Giagulli VA; Jirillo E; Guastamacchia E; Sabbà C; Triggiani V
    Front Endocrinol (Lausanne); 2022; 13():920541. PubMed ID: 36157450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.
    Wong E; Cope R; Dima L; Nguyen T
    Am J Ther; 2023 Jan-Feb 01; 30(1):e26-e35. PubMed ID: 36516422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
    Thomas MK; Nikooienejad A; Bray R; Cui X; Wilson J; Duffin K; Milicevic Z; Haupt A; Robins DA
    J Clin Endocrinol Metab; 2021 Jan; 106(2):388-396. PubMed ID: 33236115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.
    Skelley JW; Swearengin K; York AL; Glover LH
    J Am Pharm Assoc (2003); 2024; 64(1):204-211.e4. PubMed ID: 37940101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges.
    Huang X; Liu J; Peng G; Lu M; Zhou Z; Jiang N; Yan Z
    J Endocrinol; 2024 Sep; 262(3):. PubMed ID: 38916409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
    Pirro V; Roth KD; Lin Y; Willency JA; Milligan PL; Wilson JM; Ruotolo G; Haupt A; Newgard CB; Duffin KL
    J Clin Endocrinol Metab; 2022 Jan; 107(2):363-378. PubMed ID: 34608929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.